Review
Published on 30 Oct 2024
LncRNAs in tumor metabolic reprogramming and tumor microenvironment remodeling
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1467151
Type at least 3 characters
6,517 articles
Articles
Review
Published on 30 Oct 2024
The role of cuproptosis in gastric cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1435651
Review
Published on 30 Oct 2024
Oncolytic virus and CAR-T cell therapy in solid tumors
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1455163
- 112 views
Mini Review
Published on 30 Oct 2024
A single-cell perspective on immunotherapy for pancreatic cancer: from microenvironment analysis to therapeutic strategy innovation
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1454833
- 140 views
Case Report
Published on 30 Oct 2024
Primary seminal vesicle diffuse large B-cell lymphoma: a case report and review of the literatures
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1461090
- 127 views
Original Research
Accepted on 29 Oct 2024
Single-cell transcriptomics reveals heterogeneity and prognostic markers of myeloid precursor cells in acute myeloid leukemia
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1494106
Case Report
Accepted on 29 Oct 2024
Case Report: Long Remission and Survival Following Immunotherapy in a Case of Pulmonary Pleomorphic Carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1464900
Original Research
Accepted on 29 Oct 2024
Anti-PD1 therapies induce an early expansion of Ki67 + CD8 + T cells in metastatic non-oncogene addicted NSCLC patients
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1483182
Original Research
Accepted on 29 Oct 2024
Exploring RPA1-ETAA1 Axis via High-Throughput Data Analysis: Implications for PD-L1 Nuclear Translocation and Tumor-Immune Dynamics in Liver Cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1492531
Original Research
Accepted on 29 Oct 2024
COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1452035
Original Research
Accepted on 29 Oct 2024
Acute Remote Ischemic Conditioning enhances (CD3+)-but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1501885
Review
Accepted on 28 Oct 2024
The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1464327
Review
Accepted on 28 Oct 2024
Nanomaterials: breaking the bottleneck of breast cancer drug resistance
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1492546
Review
Accepted on 28 Oct 2024
The Roles of Cancer Stem Cells and Therapeutic Implications in Melanoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1486680
Review
Accepted on 28 Oct 2024
circFOXP1: A potential diagnostic and therapeutic target in human diseases
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1489378
Review
Accepted on 28 Oct 2024
IMMUNOME PROFILING IN PROSTATE CANCER: A guide for clinicians
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1398109